Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.
| Metric | BIOEN | STEM | NRGV | VGAS | FLNC | BLX | Ind. Median |
|---|---|---|---|---|---|---|---|
| P/E | — | 0.43 | — | — | — | — | 19.02 |
| P/B | 2.87 | -0.23● | 21.39 | 0.78 | 5.81 | 2.50 | 1.25 |
| EV/EBITDA | 57.33 | 1.61● | — | — | — | 14.98 | 12.12 |
| P/S | 3.11 | 0.40● | 3.00 | — | 0.83 | 4.23 | 2.91 |
| Metric | BIOEN | STEM | NRGV | VGAS | FLNC | BLX | Ind. Median |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | 0.84 | 1.44 | 35.93● | 1.43 | 1.24 | 1.07 |
| Debt/Equity | 179.1% | -123.6%● | 570.5% | 1.6% | 109.2% | 310.0% | 51.3% |
| NetDebt/EBITDA | 21.71 | 1.33 | -1.21● | 5.40 | 1.01 | 7.98 | 3.22 |
| Metric | BIOEN | AYEN | ENTRA | ENDAE | CATES | ESEN | Ind. Median |
|---|---|---|---|---|---|---|---|
| P/E | — | 34.83 | — | — | 5.20● | — | 19.02 |
| P/B | 2.87 | 0.48 | 0.22● | 0.52 | 0.50 | 0.42 | 1.25 |
| EV/EBITDA | 57.33 | 6.58 | 6.03● | 30.01 | 6.53 | 25.25 | 12.12 |
| P/S | 3.11 | 1.17 | 1.92 | 11.77 | 0.82● | 4.35 | 2.91 |
| Metric | BIOEN | AYEN | ENTRA | ENDAE | CATES | ESEN | Ind. Median |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | 0.78 | 0.34 | 4.50● | 4.26 | 0.28 | 1.07 |
| Debt/Equity | 179.1% | 36.2% | 33.2% | 2.6% | 0.8%● | 50.7% | 51.3% |
| NetDebt/EBITDA | 21.71 | 2.68 | 3.49 | -6.05● | -1.03 | 13.64 | 3.22 |
The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.
Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.